+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07551596

Study of Botensilimab and Balstilimab After Standard Therapy in Stage II or III Microsatellite Stable Colorectal Cancer with Molecular Residual Disease

Led by National Cancer Institute (NCI) · Updated on 2026-09-29

20

Participants Needed

2

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the combination of botensilimab and balstilimab for patients with stage II or III colorectal adenocarcinoma who have detectable circulating tumor DNA ctDNA after completing standard treatments. This phase II trial aims to assess whether this immunotherapy combination can help the bodys immune system attack remaining microscopic cancer cells in the bloodstream and potentially clear ctDNA as an early sign of treatment response. Participants receive balstilimab intravenously on days 1 and 22, and botensilimab intravenously on day 1 of the first two cycles. Each cycle lasts 42 days, with treatment continuing up to four cycles 6 months unless the cancer progresses or unacceptable side effects occur. Throughout the study, patients undergo urine and blood sample collections, imaging scans, and may optionally have tumor biopsies. After treatment, participants are monitored regularly for up to three years to track outcomes. During the trial, researchers measure ctDNA clearance at 3 and 6 months, recurrence-free survival, overall survival, and treatment safety. Additional assessments include tumor and plasma characteristics to predict benefit, along with monitoring changes in ctDNA profiles. Follow-up visits occur every 3 months in the first year, every 4 months in the second year, and every 6 months in the third year, unless cancer recurrence or death occurs.

CONDITIONS

Brief Title

Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here